Anti-thromboxane A2 actions of pinane thromboxane A2 derivatives.
Six pinane-thromboxane A2 analogs have been synthesized and tested for their ability to antagonize carbocyclic thromboxane A2 (CTA2) induced coronary vasoconstriction and prostaglandin endoperoxide analog induced platelet aggregation. Two of the derivatives, 5C-15S BPTA2 and 5T-15S BPTA2 and 5T-15S BPTA2 (1 microM) showed 76 +/- 3 and 72 +/- 9 percent inhibition of CTA2 (15 nM) induced vasoconstriction of cat coronary arteries respectively, while the other compounds showed between 15 and 50 percent inhibition at 1.0 and 2.0 microM. 5C-15S BPTA2 also antagonized prostaglandin-endoperoxide analog induced human platelet aggregation, although the other compounds showed little or no antagonism of aggregation in this system.
D000818:Animals; D000081008:Bicyclic Monoterpenes; D002415:Cats; D003331:Coronary Vessels / Q000187:drug effects; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects; D013928:Thromboxane A2 / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D013931:Thromboxanes / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D014661:Vasoconstriction / Q000187:drug effects
D000081008:Bicyclic Monoterpenes; D013931:Thromboxanes; D013928:Thromboxane A2; C020465:pinane-thromboxane A2